文献速递冠心病血脂与心血管预防

急性心肌梗死后替格瑞洛与氯吡格雷的疗效随肾功能分层分析

Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function.
PubMed 文献 · Heart · 2018-03-24

基于瑞典SWEDEHEART注册数据,纳入45 206例急性心肌梗死出院患者,比较替格瑞洛与氯吡格雷在eGFR分层下的1年结局。调整后替格瑞洛与较低死亡、心梗或卒中复合终点风险相关,但出血风险较高,eGFR<30患者出血事件更多。

要点

  • 替格瑞洛较氯吡格雷降低1年死亡、心梗或卒中复合终点风险,各eGFR层一致。
  • 替格瑞洛增加出血风险,eGFR<30患者出血事件更多,需谨慎。
  • eGFR<30患者替格瑞洛与氯吡格雷的复合终点风险差异无统计学意义。

核心结论

  • 在急性心肌梗死患者中,替格瑞洛较氯吡格雷与较低的死亡、心梗或卒中复合终点风险相关,但出血风险较高,各eGFR层结果一致。
  • eGFR<30患者出血事件更多,需谨慎使用替格瑞洛。

研究设计与样本

  • 基于瑞典SWEDEHEART注册的回顾性队列研究,纳入45 206例急性心肌梗死出院患者,其中氯吡格雷33 472例,替格瑞洛11 734例。
  • 使用调整的Cox比例风险模型,按eGFR水平分层分析1年结局。

主要发现

  • 未调整1年复合终点事件率:替格瑞洛组在eGFR>60、eGFR30-60、eGFR<30分别为7.0%、18.0%、48.0%;氯吡格雷组分别为11.0%、33.0%、64.0%。
  • 调整后出血风险HR:eGFR>60为1.10(95%CI 0.90-1.35),eGFR30-60为1.13(0.84-1.51),eGFR<30为1.79(1.00-3.21),交互P=0.30。

临床怎么用

  • 急性心肌梗死患者选择替格瑞洛或氯吡格雷时,应评估肾功能和出血风险。
  • eGFR<30患者使用替格瑞洛需警惕出血事件增多。

局限性

  • 观察性注册研究,可能存在残余混杂。
  • eGFR<30亚组样本量较小,置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to analyse outcomes of ticagrelor and clopidogrel stratified by estimated glomerular filtration rate (eGFR) in a large unselected cohort of patients with acute myocardial infarction (MI). METHODS: We used follow-up data in MI survivors discharged on ticagrelor or clopidogrel enrolled in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies registry. The association between ticagrelor versus clopidogrel and the primary composite outcome of death, MI or stroke and the secondary outcome rehospitalisation with bleeding diagnosis at 1 year, was studied using adjusted Cox proportional hazards models, stratifying after eGFR levels. RESULTS: In total, 45 206 patients with MI discharged on clopidogrel (n=33 472) or ticagrelor (n=11 734) were included. The unadjusted 1-year event rate for the composite endpoint of death, MI or stroke was 7.0%, 18.0% and 48.0% for ticagrelor treatment and 11.0%, 33.0% and 64.0% for clopidogrel treatment in patients with eGFR>60 (n=33 668), eGFR30-60 (n=9803) and eGFR<30 (n=1735), respectively. After adjustment, ticagrelor as compared with clopidogrel was associated with a lower 1-year risk of the composite outcome (eGFR>60: HR 0.87, 95% CI 0.76 to 99, eGFR30-60: 0.82 (0.70 to 0.97), eGFR<30: 0.95 (0.69 to 1.29), P for interaction=0.55) and a higher risk of bleeding (eGFR>60: HR 1.10, 95% CI 0.90 to 1.35, eGFR30-60: 1.13 (0.84 to 1.51), eGFR<30: 1.79 (1.00 to 3.21), P for interaction=0.30) across the eGFR strata. CONCLUSIONS: Treatment with ticagrelor as compared with clopidogrel in patients with MI was associated with lower risk for the composite of death, MI or stroke and a higher bleeding risk across all strata of eGFR. Of caution, bleeding events were more abundant in patients with eGFR<30.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Edfors R, Sahlén A, Szummer K, et al. Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function. Heart. 2018. PMID: 29574413. doi:10.1136/heartjnl-2017-312436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。